Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national centre of Hungary
Abstract Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of non-hospitalized adults with haematological malignancies diagnosed with COVID-19 and treated with early remdesivir therapy during the omicron wave. Methods A single-centre prospective cohort study was performed among adult patients between February–June 2022, during the circulation of PANGO subvariants BA.2, BA.4 and BA.5 in Hungary. Patients were enrolled based on pre-defined criteria. Clinical characteristics (demography, comorbidities, vaccination status, imaging, treatment, and disease course) and outcomes (COVID-19 related hospitalisation, oxygen supplementation, intensive care support, all-cause death) were assessed at 28-days post-treatment. Results Altogether 127 patients were enrolled: 51.2% (65/127) were female with a median age of 59 ± 22 (21‒92) years, and 48.8% (62/127) had active haematological malignancy. At 28-days post-treatment, 7.1% (9/127) of patients required COVID-19 related hospitalisation, 2,4% (3/127) required oxygen supplementation, 1,6% (2/127) required intensive care, and 0.8% (1/127) died due to a non-COVID-19 related secondary infection at the intensive care unit, all with haematological malignancies. Conclusion Early remdesivir treatment might be a feasible strategy among high-risk outpatients with haematological malignancies and COVID-19 during the omicron wave..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 16. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GÁSPÁR, Zsófia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2294671/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA037965433 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA037965433 | ||
| 003 | DE-627 | ||
| 005 | 20231017132714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221124s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2294671/v1 |2 doi | |
| 035 | |a (DE-627)XRA037965433 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2294671/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a GÁSPÁR, Zsófia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of high-risk adult outpatients with haematological malignancies treated with early remdesivir therapy during the SARS-CoV-2 omicron era: experiences from the national centre of Hungary |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of non-hospitalized adults with haematological malignancies diagnosed with COVID-19 and treated with early remdesivir therapy during the omicron wave. Methods A single-centre prospective cohort study was performed among adult patients between February–June 2022, during the circulation of PANGO subvariants BA.2, BA.4 and BA.5 in Hungary. Patients were enrolled based on pre-defined criteria. Clinical characteristics (demography, comorbidities, vaccination status, imaging, treatment, and disease course) and outcomes (COVID-19 related hospitalisation, oxygen supplementation, intensive care support, all-cause death) were assessed at 28-days post-treatment. Results Altogether 127 patients were enrolled: 51.2% (65/127) were female with a median age of 59 ± 22 (21‒92) years, and 48.8% (62/127) had active haematological malignancy. At 28-days post-treatment, 7.1% (9/127) of patients required COVID-19 related hospitalisation, 2,4% (3/127) required oxygen supplementation, 1,6% (2/127) required intensive care, and 0.8% (1/127) died due to a non-COVID-19 related secondary infection at the intensive care unit, all with haematological malignancies. Conclusion Early remdesivir treatment might be a feasible strategy among high-risk outpatients with haematological malignancies and COVID-19 during the omicron wave. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a SZABÓ, Bálint Gergely |4 aut | |
| 700 | 1 | |a ÁBRAHÁM, Anita |4 aut | |
| 700 | 1 | |a VÁRNAI, Zsuzsanna |4 aut | |
| 700 | 1 | |a KISS-DALA, Noémi |4 aut | |
| 700 | 1 | |a SZLÁVIK, János |4 aut | |
| 700 | 1 | |a SINKÓ, János |4 aut | |
| 700 | 1 | |a VÁLYI-NAGY, István |4 aut | |
| 700 | 1 | |a LAKATOS, Botond |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 16. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00210-023-02456-y |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2294671/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 10 | ||